NVIV
Income statement / Annual
Last year (2022), InVivo Therapeutics Holdings Corp.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, InVivo Therapeutics Holdings Corp.'s net income was -$10.18 M.
See InVivo Therapeutics Holdings Corp.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$445,000.00 |
$372,000.00 |
$329,000.00 |
$322,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$445,000.00 |
-$372,000.00 |
-$329,000.00 |
-$322,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$5.23 M
|
$4.38 M
|
$3.94 M
|
$5.60 M
|
$4.93 M
|
$11.08 M
|
$12.56 M
|
$10.06 M
|
$10.27 M
|
$10.53 M
|
| General & Administrative
Expenses |
$5.42 M
|
$5.52 M
|
$5.16 M
|
$5.90 M
|
$7.84 M
|
$13.51 M
|
$11.51 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5.42 M
|
$5.52 M
|
$5.16 M
|
$5.90 M
|
$7.84 M
|
$13.51 M
|
$11.51 M
|
$12.34 M
|
$7.57 M
|
$8.47 M
|
| Other Expenses |
$9,000.00 |
$2,000.00 |
$4,000.00 |
$79,000.00 |
$1.30 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$10.65 M |
$9.90 M |
$9.10 M |
$11.50 M |
$12.77 M |
$24.59 M |
$24.06 M |
$22.40 M |
$17.84 M |
$19.01 M |
| Cost And Expenses |
$10.65 M |
$9.90 M |
$9.10 M |
$11.50 M |
$12.77 M |
$24.59 M |
$24.06 M |
$22.40 M |
$17.84 M |
$19.01 M |
| Interest Income |
$151,000.00 |
$3,000.00 |
$19,000.00 |
$255,000.00 |
$0.00 |
$189,000.00 |
$187,000.00 |
$60,000.00 |
$5,000.00 |
$15,279.00 |
| Interest Expense |
$151,000.00 |
$0.00 |
$19,000.00 |
$254,000.00 |
$206,000.00 |
$74,000.00 |
$155,000.00 |
$172,000.00 |
$136,000.00 |
$129,902.00 |
| Depreciation &
Amortization |
$445,000.00
|
$372,000.00
|
$329,000.00
|
$988,000.00
|
$12.26 M
|
$395,000.00
|
$553,000.00
|
$689,000.00
|
$752,000.00
|
$740,692.00
|
| EBITDA |
-$10.21 M
|
-$9.53 M
|
-$8.77 M
|
-$10.59 M
|
-$23.13 M
|
-$26.28 M
|
-$22.73 M
|
-$32.45 M
|
-$17.08 M
|
-$19.37 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$160,000.00
|
$5,000.00
|
$23,000.00
|
-$333,000.00
|
-$10.66 M
|
-$3.05 M
|
$625,000.00
|
-$10.92 M
|
-$507,000.00
|
-$19.75 M
|
| Income Before Tax |
-$10.49 M |
-$9.90 M |
-$9.07 M |
-$11.83 M |
-$23.42 M |
-$26.75 M |
-$23.44 M |
-$33.31 M |
-$18.35 M |
-$38.76 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$311,000.00 |
-$3,000.00 |
-$19,000.00 |
$412,000.00 |
$22.82 M |
$2.27 M |
-$593,000.00 |
$10.80 M |
$376,000.00 |
$19.64 M |
| Net Income |
-$10.18 M |
-$9.89 M |
-$9.06 M |
-$12.24 M |
-$46.24 M |
-$26.75 M |
-$23.44 M |
-$33.31 M |
-$18.35 M |
-$38.76 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-6.62 |
-7.47 |
-32.8 |
-912.63 |
-6950.85 |
-15221.97 |
-14170.5 |
-23610.21 |
-15587.09 |
-36910.4 |
| EPS Diluted |
-6.62 |
-7.47 |
-32.8 |
-912.63 |
-6950.85 |
-15221.97 |
-14170.5 |
-23610.21 |
-15587.09 |
-36910.4 |
| Weighted Average Shares
Out |
$1.54 M
|
$1.32 M
|
$276,107.00
|
$13,414.00
|
$6,653.00
|
$1,757.00
|
$1,654.00
|
$1,411.00
|
$1,177.00
|
$1,050.00
|
| Weighted Average Shares
Out Diluted |
$1.54 M
|
$1.32 M
|
$276,107.00
|
$13,414.00
|
$6,653.00
|
$1,757.00
|
$1,654.00
|
$1,411.00
|
$1,177.00
|
$1,050.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
